SAN FRANCISCO, June 23, 2016 /PRNewswire/ -- EpiBiome, a precision microbiome engineering company, today announced it has secured $1 million in debt financing from Silicon Valley Bank (SVB). The financing will allow EpiBiome to ramp up automation and to advance its drug development efforts, as well as purchase additional lab equipment for its new facility.
"SVB has been an incredible strategic partner to us – one that goes beyond the services a traditional bank would provide," said Dr. Aeron Tynes Hammack, EpiBiome's co-founder and chief operating officer. "They've helped connect us with corporate partners and investors while also producing life sciences reports that perfectly analyze our target markets. These insights and connections have played a significant role in our success."
This financing announcement follows the January close of EpiBiome's $6 million Series A funding round. Leading next-generation sequencing investors from the round included Viking Global Investors via Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures, China Rock Capital Management and China Ding Cheng Holding Group.
Adding to its accolades and accomplishments, EpiBiome was a graduate from the inaugural class of Illumina Accelerator, the world's first business accelerator that focuses on helping genomic companies launch.
"We've been working with EpiBiome for nearly two years, and it's our pleasure to continue the partnership," said Jennifer Friel Goldstein, managing director at Silicon Valley Bank. "Through Illumina Accelerator, we really saw EpiBiome's potential to dramatically reduce the threat of antibiotic resistance in agriculture. We're excited to support their continued advancements in tackling infectious diseases through microbiome engineering – which shows beneficial promise to both the agricultural space and human health."
EpiBiome's mission is to develop effective, sustainable FDA-approved therapies to combat infectious disease in humans and agriculture without the use of antibiotics. For more information on the microbiome engineering company, visit http://www.epibiome.com.
EpiBiome is a venture-backed precision microbiome engineering company working to curb the growing threat of multi-drug-resistant superbugs by eliminating the use of shared-class antibiotics, those shared between humans and animals, from agriculture.
The company's management team consists of Nick Conley, PhD (Chief Executive Officer and Co-Founder), Aeron Tynes Hammack, PhD (Chief Operating Officer & Co-Founder), Christina Tsai, PhD (Chief Science Officer & Co-Founder), Lucia Mokres, DVM (Chief Medical Officer), and Bruno Marchon, PhD (Chief Technical Officer). EpiBiome is located at 201 Gateway Blvd., South San Francisco, California 94080. For more information, visit http://www.epibiome.com.
About Silicon Valley Bank
For more than 30 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epibiome-receives-1m-in-debt-financing-from-silicon-valley-bank-300288933.html